Related by context. All words. (Click for frequent words.) 77 Pharmacodynamic 75 Pharmacokinetic PK 73 pharmacokinetic PK 71 Long Term Efficacy 71 fosbretabulin 71 Tolerability 70 Antiviral Activity 70 pharmacokinetics PK 70 Pharmacodynamics 70 pharmacodynamic PD 70 dose proportionality 69 pharmacokinetic 69 Randomized Double blind 69 Pivotal Phase III 69 Prospective Randomized 69 Meets Primary Endpoint 69 Oral Fingolimod 68 Phase 2b Clinical Trial 68 Clinical Trial Results 68 pharmacodynamic effects 68 Controlled Trial 68 Monotherapy 68 Pharmacokinetic Study 68 Statistically Significant 68 Pharmacokinetics 68 pharmacodynamic parameters 68 Safinamide 68 pharmacokinetic parameters 68 BAL# [002] 68 SABCS 68 Pharmacokinetics PK 68 Antitumor Activity 68 Dose Response 68 Epoetin Alfa 68 Phase 2b Study 68 Phase III Trial 68 II Clinical Trial 68 Anti Tumor 68 pharmacodynamic 67 Phase 2b Trial 67 Double Blind Randomized 67 ritonavir boosted 67 JAK Inhibitor 67 Study Evaluating 67 Immunogenicity 67 Tiotropium 67 Pooled Analysis 67 Preclinical Study 67 Vildagliptin 67 Relapsing Multiple Sclerosis 67 Fulvestrant 67 Efficacy 67 Safety Tolerability 67 hematological parameters 67 Pharmacokinetic parameters 67 plasma pharmacokinetics 67 Investigational Compound 67 galiximab 67 Acute Ischemic Stroke 67 Mycophenolate Mofetil 66 Investigational Drug 66 Platelet Inhibition 66 Well Tolerated 66 Hepatotoxicity 66 Phase IIb Trial 66 Double Blind Placebo 66 Patients Receiving 66 Prospective Randomized Trial 66 Anti Tumor Activity 66 Cardiotoxicity 66 safety tolerability pharmacokinetic 66 Randomised 66 MERLIN TIMI 66 Stent Restenosis 66 BARACLUDE ® 66 riociguat 66 Pioglitazone 66 Placebo Controlled Trial 66 Randomized Double Blind 66 relapsed MM 66 EURIDIS 66 Capsules CII 66 Survival Benefit 66 See CLINICAL PHARMACOLOGY 66 Hemodialysis Patients 66 viral kinetics 66 Dose Escalation 66 Newly Diagnosed Multiple Myeloma 66 Patients Treated With 66 Initiate Phase 66 Teriflunomide 66 PEG IFN 66 Phase IIb Clinical Trial 66 Clinical Outcome 66 Randomized Phase 66 Aflibercept 66 Antiangiogenic 66 Pivotal Phase 66 pharmacokinetic PK profile 65 Hsp# Inhibitor 65 Prolongs Survival 65 guanfacine extended release 65 CLORETAZINE TM VNP#M 65 PRTX 65 alpha 2a 65 Novel Oral 65 pharmacokinetic PK study 65 Clinical Efficacy 65 Tumor Response 65 Relapsing Remitting Multiple Sclerosis 65 Demonstrated Significant 65 Phase III Clinical Trial 65 Ziprasidone 65 TMC# [002] 65 Randomized Double Blind Placebo 65 Linagliptin 65 Orally Active 65 pharmacodynamics PD 65 Preclinical Data 65 Solid Tumors 65 BOLDER II 65 pharmacokinetic pharmacodynamic 65 Bosutinib 65 Histologic 65 Protease Inhibitors 65 Randomized Phase II 65 Antipsychotic 65 Pegylated Liposomal Doxorubicin 65 Anticancer Activity 65 viral kinetic 65 Peginterferon 65 preclinical efficacy 65 Neuroprotective Effects 65 Enzastaurin 65 Virologic 65 analgesic efficacy 65 Drug Candidate 65 ORENCIA ® 65 Pegylated 65 Nymox NX 65 BRIM3 65 Demonstrates Potent 65 RE LY trial 65 prucalopride 65 Adalimumab 64 phase Ib 64 teriflunomide 64 Adjuvant Therapy 64 Hormone Refractory Prostate Cancer 64 oral FTY# 64 Subgroup analysis 64 Hematologic 64 Randomized Controlled 64 beta 1a 64 Pivotal Study 64 GLYX 64 pharmacodynamic properties 64 icatibant 64 Patency 64 Echocardiographic 64 favorable pharmacokinetic profile 64 Multicenter 64 Study Showed 64 Val HeFT 64 Controlled Study 64 Meta Analysis 64 NSABP B 64 Tipranavir 64 Antihypertensive 64 candesartan cilexetil 64 TAXUS ATLAS 64 Kidney Function 64 Renal Cell Carcinoma 64 Lp PLA 2 64 pharmacokinetic interactions 64 desvenlafaxine succinate 64 Peginterferon Alfa 2a 64 atazanavir ritonavir 64 Demonstrates Efficacy 64 Demonstrate Significant 64 Sustained Efficacy 64 nab paclitaxel 64 AVADO 64 Golimumab 64 davunetide intranasal AL 64 Microalbuminuria 64 HuMax EGFr 64 fluvastatin 64 Sapacitabine 64 Metastatic Melanoma 64 Bioavailability 64 Oral Formulation 64 GOUT 64 multicentre randomized 64 Adverse Event 64 Initiated Phase 64 limiting toxicity DLT 64 Ranolazine 64 Interferon Gamma 64 Clinical Trial Data 64 glycosylated hemoglobin HbA1c 64 antidepressant efficacy 64 CALGB # [002] 63 Pafuramidine 63 abacavir Ziagen 63 Xelox 63 Kahalalide F 63 Aliskiren 63 DASISION 63 efavirenz EFV 63 PKC# 63 GAMMAGARD 63 Edge STudy 63 TRANSFORMS 63 HDAC Inhibitor 63 Randomized Evaluation 63 Novel Inhibitor 63 Telbivudine 63 Bioequivalence 63 GSK# [001] 63 Teriparatide 63 Potent Inhibitor 63 ATACAND 63 Intervention Effectiveness 63 multicenter multinational 63 APTIVUS r 63 Phase IIB 63 AST ALT 63 Blood Pressure Lowering 63 Sipuleucel T 63 QD dosing 63 PEGylated interferon beta 1a 63 Pegylated Interferon 63 Previously Treated 63 Investigational Agent 63 nonrandomized 63 Phase III Clinical Trials 63 Denufosol 63 antiviral efficacy 63 PERSEUS 63 aclidinium 63 BRIM2 63 Randomized Study 63 Diabetic Nephropathy 63 Phase Ib study 63 FOLPI 63 TO AVOID PREGNANCY WHILE 63 INCB# [001] 63 Insulin Glargine 63 Autologous Stem Cell Transplantation 63 Severe Sepsis 63 Late Breaker 63 Primary Endpoint 63 oral prodrug 63 Nebulized 63 Chronic Hepatitis C 63 ZOLINZA 63 Placebo Controlled Study 63 mapatumumab 63 Interferon Beta 63 Metastatic Renal Cell Carcinoma 63 Bivalirudin 63 Ambrisentan 63 Kinase Inhibitor 63 Postmarketing 63 Capecitabine 63 Dose Ranging Study 63 Pharmacologic 63 Phase 2a Trial 63 Antitumor 63 CIMZIA TM certolizumab pegol 63 Hypercholesterolemia 63 Multiple Ascending Dose 63 Omacetaxine 63 Pivotal Trial 63 unfractionated heparin UFH 63 UPLYSO 63 phase IIIb 63 pharmacokinetics 63 QTc 63 Lung Cancer Trial 63 SPRYCEL ® 63 tumor histology 63 pharmacokinetic characteristics 63 Plus Ribavirin 63 Unfractionated Heparin 63 Pulmonary Arterial Hypertension 63 ganetespib 63 Demonstrates Positive 63 crizotinib PF # 63 Sandostatin R 63 Potent Antiviral Activity 63 Phase 2a Clinical Trial 63 Combination Therapy 63 Treprostinil 63 Protease Inhibitor 63 Glufosfamide 63 Ambulatory Blood Pressure 63 Topline Results 63 Single Dose 63 Darbepoetin Alfa 63 RECIST Response Evaluation Criteria 63 Improves Outcomes 63 Glatiramer Acetate 63 LAF# 63 HCV Protease Inhibitor 63 Randomized Clinical Trial 63 Phase IIA 63 topically administered 63 Danazol 63 Lamotrigine 63 Treated Patients 63 Is Well Tolerated 63 ULORIC 63 Carfilzomib 63 KRN# 63 Shows Efficacy 63 ExTRACT TIMI 63 ENDEAVOR IV 63 Patients Treated 63 HIV RNA 63 oral rivaroxaban 63 Epratuzumab 63 CIMZIA TM 63 alfa 2a 63 rHuPH# 63 Bortezomib 63 Demonstrates Significant 63 ara C 62 RE LY ® 62 blinded randomized placebo controlled 62 TLUS 62 Iloperidone 62 Subgroup Analysis 62 Phase 1a clinical 62 melphalan prednisone 62 lactate dehydrogenase LDH 62 ADAGIO study 62 CALGB 62 liposomal amphotericin B 62 Neoadjuvant 62 serum cortisol 62 Parathyroid Hormone 62 Phase Ib Clinical Trial 62 R# #mg BID 62 Betaferon R 62 solithromycin 62 Pemetrexed 62 mGluR5 NAM 62 Zenvia Phase III 62 Cloretazine 62 Immunosuppression 62 clevidipine 62 prospective multicentre 62 APTIVUS 62 reactogenicity 62 S/GSK# 62 Mg Uk 62 randomized multicenter trial 62 administered subcutaneously 62 Hypertensive Patients 62 Cytochrome P# 62 Doxil ® 62 genotypic resistance 62 Recombinant Human 62 Dendritic Cells 62 AZILECT R 62 Depressive Symptoms 62 intermittent dosing 62 Fixed Dose 62 favorable tolerability 62 Trial Evaluating 62 Tyrosine Kinase Inhibitor 62 pharmacokinetics pharmacodynamics 62 PROSTVAC TM 62 MGd 62 epoetin alpha 62 5 Fluorouracil 62 Blind Placebo Controlled Trial 62 Aurora Kinase 62 Phase 2a Study 62 Multicenter Phase 62 Pharmacokinetic Pharmacodynamic 62 Calcium Acetate 62 Skeletal Muscle 62 biodistribution 62 Disease Progression 62 alvespimycin 62 zonisamide SR 62 Adenoma Prevention 62 coadministration 62 prospectively defined 62 preclinical pharmacokinetic 62 sitaxsentan 62 Metabolic Efficiency 62 Ozarelix 62 PREVENT IV 62 Phase III Trials 62 Phase Ib clinical 62 ziprasidone 62 Natalizumab 62 pomalidomide 62 RE SURGE 62 Mg Usa 62 Medoxomil 62 Bisphosphonate 62 Known hypersensitivity 62 Investigational Treatment 62 Clinical Evaluation 62 lispro 62 Xeloda ® 62 Fondaparinux 62 ibandronate 62 CIMZIA ™ 62 Polymerase Inhibitor 62 Forodesine HCl 62 bendamustine 62 CANCIDAS 62 Histological 62 Patient Outcomes 62 Therapeutic Potential 62 Showed Significant 62 Darusentan 62 plus prednisone 62 tirofiban 62 EGFR TKI 62 Phase IIa Clinical Trial 62 demonstrated clinically meaningful 62 NDA Submission 62 subanalysis 62 DOXIL 62 demonstrated antitumor activity 62 Aclidinium 62 Left Ventricular Dysfunction 62 Trandolapril 62 pegylated interferon alfa 2b 62 Active Ulcerative Colitis 62 pharmacokinetic studies 62 Blinatumomab 62 CINQUIL 62 Pharmacokinetic studies 62 Synthetic Peptide 62 #mg dose [001] 62 Protelos R 62 Phase 1b trial 62 Versus Placebo 62 CDK inhibitor 62 oral antidiabetic medication 62 PK PD 62 Triapine R 62 Infected Patients 62 serum phosphate 62 Vicriviroc 62 Interferon beta 1a 62 Dose Escalation Study 62 Colorectal Cancer Patients 62 evaluating tivozanib 62 Lipid Levels 62 abacavir lamivudine 62 azilsartan medoxomil 62 Presents Positive 62 Presents Preclinical Data 62 Follicular Lymphoma 62 RNAi Therapeutic 62 certolizumab 62 Bosentan 62 IFN α 62 EDEMA3 trial 62 ORMD 62 CLARITY study 62 receptor tyrosine kinase inhibitor 62 posaconazole 62 Diabetic Neuropathy 62 Primary endpoints 62 Valsartan 62 vidofludimus 62 elotuzumab 62 satraplatin Phase 62 Treatment Naive HIV 62 Efficacy Results 62 Phase Ib II 61 Preclinical Models 61 Benign Prostatic Hyperplasia 61 NATRECOR ® 61 florbetaben 61 serum leptin 61 Demonstrates Statistically Significant 61 ® pioglitazone HCl 61 tipifarnib 61 nicardipine 61 pharmacokinetic pharmacodynamic PK PD 61 Xanafide 61 divalproex sodium 61 BCIRG 61 Clinical Trial Evaluating 61 Decitabine 61 #th Annual Interscience 61 amprenavir 61 #μg [002] 61 tipranavir r 61 NPH insulin 61 ALB # 61 SPIRIT FIRST 61 Glycemic Control 61 Postmenopausal Women 61 anti leukemic 61 RLAI 61 secondary efficacy endpoints 61 maximally tolerated dose 61 phase IIa 61 pharmacodynamic PK PD 61 Dasatinib 61 Elagolix 61 basal bolus regimen 61 INC# 61 Immunomodulatory 61 pioglitazone HCl 61 DAVANAT 61 Nucleoside 61 CLINICAL PHARMACOLOGY 61 Elderly Patients 61 Improves Survival 61 relapsed myeloma 61 Kaplan Meier analysis 61 TMC# C# 61 MAGE A3 ASCI 61 Randomized controlled 61 evaluating mipomersen 61 Treatment Naive Patients 61 Schizophrenia Treatment 61 Bone Mineral Density 61 multicenter randomized controlled 61 INCB# [003] 61 Relapsed Multiple Myeloma 61 Combination Treatment 61 selective modulator 61 BENICAR HCT 61 Desvenlafaxine Succinate 61 Clinical Outcomes 61 REYATAZ R 61 STRIDE PD 61 Lacosamide 61 favorable pharmacokinetic 61 canakinumab 61 liposome injection 61 dose escalation phase 61 p# biomarker 61 antiretroviral naive 61 Deforolimus 61 Lupus Drug 61 IMPACT DCM 61 SVR# 61 Eculizumab 61 Randomized Controlled Trials 61 Low Dose 61 Nonalcoholic Steatohepatitis 61 fosamprenavir 61 Melphalan 61 Tezampanel 61 velafermin 61 mg/m2 dose 61 Nonclinical 61 efficacy tolerability 61 Non Responders 61 treatment naive genotype 61 Zoledronic Acid 61 Main Outcome Measure 61 Phase IIIb 61 LEXIVA r 61 Phase III Pivotal Trial 61 Placebo Controlled 61 IL# PE#QQR 61 baseline LDH 61 Receptor Antagonists 61 aspartate aminotransferase AST 61 Adjunctive Therapy 61 Bucindolol 61 Attenuates 61 Metastatic Prostate Cancer 61 Diabetic Patients 61 First Patient Enrolled 61 oral ibandronate 61 VADT 61 PEG SN# 61 Suicidality 61 intravenous dosing 61 Mimetics 61 Pediatric Patients 61 pharmacodynamic profiles 61 Zoraxel 61 peginesatide 61 RE LY 61 DLTs 61 Nilotinib 61 QTc prolongation 61 plasma lipid 61 colesevelam 61 multicenter randomized placebo controlled 61 Treating Chronic 61 PROCRIT R 61 Adjuvant Treatment 61 LB# [003] 61 Statin Therapy 61 eculizumab therapy 61 #mg BID [003] 61 HCV SPRINT 61 tolvaptan 61 pharmacodynamic profile 61 Afatinib 61 Intravitreal 61 antiangiogenic therapy 61 FOLOTYN ® 61 TLK# 61 corrected QT interval 61 virological response 61 Naive Patients 61 IND Application 61 REMINYL ® 61 First Patient Dosed 61 comparator arm 61 ascending doses 61 Sustained Release 61 somatostatin analog 61 Talactoferrin 61 Patient Enrollment 61 NHANES III 61 Universal Flu Vaccine 61 Extended Release 61 Cardiovascular Outcomes 61 Anthracycline 61 vitro cytotoxicity 61 Septic Shock 61 EGS# 61 atazanavir sulfate 61 Apoptone 61 neratinib 61 Secondary endpoints 61 dose dependently 61 Lipid Lowering Treatment 61 Antiepileptic Drug 61 Pharmacological 61 Phase 1a 61 subcutaneously administered 61 ACCOMPLISH 61 Fracture Risk 61 novel VDA molecule 61 Histopathologic 61 transdermal estradiol 61 EXPAREL ™ 61 intravascular hemolysis 61 Refractory Hodgkin Lymphoma 61 multicenter Phase II 61 virologic response 61 FASLODEX 61 Heart Failure Patients 61 Initiates Clinical 61 delafloxacin 61 Advanced Melanoma 61 ON #.Na 61 R lenalidomide 61 Medullary Thyroid Cancer 61 tipranavir 61 LEXIVA 61 Long Lesion 61 tolerability pharmacokinetics 61 dapagliflozin plus 61 RECORD1 61 ISTODAX ® 61 SUTENT ® 61 PXD# 61 Traficet EN 61 Etanercept 61 covariance ANCOVA 61 Excretion 61 Avanafil 61 varespladib 61 Shows Promising 61 PegIFN RBV 61 8mg/kg 61 Capesaris 61 Inflammatory Markers 61 Cardiac Resynchronization 61 Tanespimycin 61 cannabinor 61 Receptor Agonist 61 hyperphenylalaninemia HPA due 61 ascending dose 61 PEGINTRON TM 61 Meta analyzes 61 dosage regimens 61 Antiplatelet 61 CR# vcMMAE 61 Femara letrozole 61 antiviral potency 61 dual endothelin receptor antagonist 61 fluticasone furoate 61 haematologic 61 Granted Orphan Drug 61 HCV Genotype 61 MYCAMINE 61 nonclinical studies 61 Acute Myocardial Infarction 61 peginterferon alpha 2a 61 Myocardial Perfusion 60 achieved statistical significance 60 CCyR 60 VP# [004] 60 CAMMS# 60 Novel Antibiotic 60 ACTEMRA TM 60 Tolvaptan 60 alemtuzumab MS 60 tipranavir ritonavir 60 Treatment Resistant 60 Castration Resistant Prostate Cancer 60 #mg/day [002] 60 tocilizumab 60 Darinaparsin 60 Improved Survival 60 standard chemotherapy regimen 60 huN# DM1 60 sorafenib Nexavar 60 Carvedilol 60 active comparator 60 ISIS # 60 Daptomycin 60 trodusquemine 60 virus HCV protease inhibitor 60 pharmacodynamic endpoints 60 platelet reactivity 60 aripiprazole Abilify 60 Bare Metal Stent 60 NAbs 60 4mg/kg 60 Stent Thrombosis 60 Myocardial Infarction 60 Significant Efficacy 60 Atypical Antipsychotic 60 Archexin 60 Tasigna prolongs 60 Cardiovascular Events 60 refractory chronic lymphocytic 60 Prognostic Value 60 Ophena TM 60 GRNCM1 60 Efficacy Study 60 Seliciclib 60 Posaconazole 60 Aplidin 60 Androxal TM 60 C Reactive Protein 60 CTAP# Capsules 60 dose cohort 60 Intervention Trial 60 insulin detemir 60 HGS ETR2 60 Clinical Antipsychotic Trials 60 Postoperative 60 HORIZONS AMI trial 60 mg kg dose 60 LT NS# 60 Androgen Receptor 60 EGFR HER2 60 Adjuvant Chemotherapy 60 Aripiprazole 60 Mutational 60 CHARM Added 60 MEND CABG II 60 Clinical Relevance 60 MERIT ES 60 AEGR 60 Achieves Primary Endpoint 60 Neoadjuvant Chemotherapy 60 sitagliptin Januvia 60 papillary renal cell carcinoma 60 ACTOS ® 60 Successfully Completes Phase 60 Novel Mechanism 60 INFERGEN 60 ziprasidone Geodon 60 salmeterol fluticasone 60 clomipramine 60 Immunohistochemical 60 ezetimibe simvastatin 60 Targeted Therapy 60 Novel Therapeutic 60 Cethromycin 60 Generalized Anxiety Disorder 60 AAG geldanamycin analog 60 CCX# B 60 antitumour activity 60 Estrogen Receptor 60 brivaracetam 60 Left Ventricular 60 Disease Modifying 60 LCP AtorFen 60 Zoloft sertraline 60 Moxifloxacin 60 Gemcitabine 60 Relapsed Refractory 60 Protein Expression 60 statistical significance p 60 sunitinib Sutent ® 60 Hormone Receptor Positive 60 Infliximab 60 Triolex 60 recurrent glioblastoma multiforme 60 Valortim R 60 ARCOXIA 60 Chemophase 60 pan HDAC inhibitor 60 OBPM 60 Budesonide 60 serum phosphorus 60 statistically significant efficacy 60 cinacalcet 60 Prostate AdenoCarcinoma Treatment 60 oxycodone CR 60 alanine aminotransferase 60 Initiate Clinical Trial 60 Bevacizumab 60 lanthanum carbonate 60 Anticoagulant 60 Enoxaparin 60 lacosamide 60 AIR2 Trial 60 placebo controlled clinical 60 Multiple Myeloma Patients 60 ENDEAVOR III 60 Breast Density 60 XIENCE V PROMUS Stent 60 HMG CoA reductase inhibitors 60 Albuminuria 60 gemcitabine carboplatin 60 Completes Patient Enrollment 60 Antidiabetic 60 Percutaneous Tibial Nerve Stimulation 60 febuxostat 60 multicenter placebo controlled 60 Cariprazine 60 Overactive Bladder 60 Treatment Outcome 60 response CCyR 60 multicenter phase 60 alfuzosin 60 Myelodysplastic Syndromes 60 GAMMAGARD LIQUID 60 Viral Suppression 60 pharmacodynamics 60 daily Infergen 60 serum concentrations 60 CG# [003] 60 myocardial uptake 60 Synta Announces 60 surrogate endpoint 60 Pivotal Phase II 60 decitabine 60 Peginterferon Alfa 2b 60 AVAPRO 60 Combination REOLYSIN R 60 Orthostatic Hypotension 60 mg kg BID 60 neoadjuvant 60 uricase 60 Non Inferiority 60 Atomoxetine 60 PSMA ADC 60 Partial Onset Seizures 60 COSTAR II 60 APPRAISE 60 QLT# 60 EQUETRO 60 liposomal formulation 60 β blockers 60 pharmacokinetic profiles 60 Cloretazine ® 60 GHRH 60 HORIZONS AMI 60 Ibritumomab Tiuxetan 60 Regimens 60 COPERNICUS 60 systemically administered 60 Bare Metal Stents 60 Diabetic Foot Ulcer 60 tanespimycin 60 Non inferiority 60 AVERROES 60 Azacitidine 60 Cinacalcet 60 Darunavir 60 Randomized Clinical Trials 60 Shows Statistically Significant 60 HIV HCV coinfected 60 mesalamine granules 60 Nesiritide 60 Immunotherapeutic 60 BoNTA 60 HER2 expression 60 #mg dose [002] 60 Hedgehog Pathway Inhibitor 60 MDS MPD 60 preclinical pharmacology 60 colesevelam HCl 60 Subgroup analyzes 60 HCV RESPOND 2 60 glomerular filtration 60 Risk Stratification 60 #th Interscience Conference 60 tigecycline 60 BARI 2D 60 Renal Function 60 Univariate 60 Panzem R NCD 60 metastatic malignant 60 Novel Compound 60 pharmacokinetic profile 60 alvimopan 60 Anti TNF 60 Corticosteroid 60 radezolid 60 PREZISTA ritonavir 60 LUMINATE 60 Methylnaltrexone 60 Chronic Heart Failure 60 GMX# 60 paricalcitol 60 tolerability profiles 60 mg BID 60 immunological responses 60 TACI Ig 60 intima media thickness IMT 60 urate lowering 60 Ropinirole 60 CYP#A# CYP#D# 60 AZT zidovudine Retrovir 60 Azedra 60 Inhalation Solution 60 TRO# 60 Elitek 60 MIRCERA 60 F FDG PET 60 Pazopanib 60 Vidofludimus 60 cMET 60 Systemic Delivery 60 sorafenib tablets 60 Vidaza azacitidine 60 confirmatory clinical 60 urocortin 2 60 metastatic castration resistant 60 Taxotere ® 60 peripheral blood mononuclear 60 PSN# [002] 60 Tigecycline 60 Venous Thromboembolism 60 PS# [001] 60 Phase IIIb clinical 60 Coronary CTA 60 randomized Phase IIb 60 erlotinib Tarceva ® 60 EVEREST II 60 ACCORD Lipid 60 albiglutide 60 irbesartan 60 Unstable Angina 60 Cognitive Impairment 60 Phase 1b Clinical Trial 60 6MWD 60 Phase #/#a 60 Advanced Renal Cell 60 Dual Antiplatelet Therapy 60 P#Y# [002] 60 elevated creatinine 59 Initiates Phase III 59 CLIRS 59 huC# DM4 59 immunostaining 59 Pimavanserin 59 Tesamorelin 59 Inhaled Liposomal Ciprofloxacin 59 lopinavir r 59 Potent Anti 59 ROCKET AF 59 LibiGel ® 59 KRAS status 59 BMS# 59 Voreloxin 59 DU #b 59 Selective Cardiac Myosin Activator 59 BARACLUDE R 59 tumorigenicity 59 Postmenopausal Osteoporosis 59 Multivariate logistic regression 59 Myelodysplastic Syndrome MDS 59 cisplatin gemcitabine 59 Demonstrates Sustained 59 VAPRISOL 59 Significantly Improved 59 PREZISTA r